🇺🇸 FDA
Patent

US 11690918

Pyrrolobenzodiazepine-anti-CD22 antibody conjugates

granted A61KA61K2039/505A61K31/551

Quick answer

US patent 11690918 (Pyrrolobenzodiazepine-anti-CD22 antibody conjugates) held by ADC THERAPEUTICS SA expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ADC THERAPEUTICS SA
Grant date
Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K31/551, A61K31/5517, A61K39/001113